Archived Press

ProPhase Stock Quote

PRPH
Last
2.28
Change
0.01 (0.4%)

2016 ProPhase Labs Annual Report

ProPhase Labs to Release Fourth Quarter Results on Tuesday, March 6th

02-29-2012 10:51:49
Press Release

DOYLESTOWN, PA – February 29, 2012 - ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the fourth quarter and the year ended December 31, 2011, will be released before the market opens on Tuesday, March 6, 2012.

 

###

 

About ProPhase Labs

 

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories LLC ("Phusion").  Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds.  Phusion will formulate and test products to exploit market opportunities within ProPhase’s robust OTC distribution channels. For more information visit us at www.ProPhaseLabs.com.

 

Press Only Contact: 

Jenny Miranda 

5W Public Relations

Tel: (212) 584-4295

jmiranda@5wpr.com

 

Investor Relations:

Ted Karkus

Chairman of the Board, CEO

(215) 345-0919 x0